Table 2.
Outcome domains reported in 57 randomised controlled trials classified using the Williamson and Clarke Taxonomy
| Bladder cancer morphology | Studies | CLINICAL | DEATH | ADVERSE EVENTS | LIFE IMPACT | RESOURCE USE | |||||
| TUMOR RELATED OUTCOMES | SURVIVAL | DELIVERY OF CARE | GLOBAL QUALITY OF LIFE | ECONOMIC | |||||||
| Recurrence | Progression | Treatment response (for cis) | Overall survival | Cancer-specific survival | Adverse events | Completion/adherence | Treatment failure/change of treatment reported (RC,RT) | Quality of life | Health Economics | ||
| CIS+/- PAPILLARY | Lamm 2000 | x | x | x | x | x | x | x | |||
| Palou 2001 | x | x | x | x | x | x | |||||
| Au 2001 | x | x | |||||||||
| Sekine 2001 | x | x | x | x | x | ||||||
| Martinez-Pinneiro 2002 | x | x | x | x | x | x | x | ||||
| Di Stasi 2003 | x | x | x | x | x | x | x | ||||
| Kaasinen 2003 | x | x | x | x | x | ||||||
| Martinez-Pinneiro 2005 | x | x | x | x | |||||||
| de Reijke 2005 | x | x | x | x | x | ||||||
| di Stasi 2006 | x | x | x | x | x | x | |||||
| Gårdmark 2007 | x | x | x | x | |||||||
| Cai 2008 | x | x | x | x | |||||||
| Neple 2010 | x | x | |||||||||
| Porena 2010 | x | x | x | ||||||||
| Koga2010 | x | x | x | x | x | ||||||
| Gülınar 2012 | x | x | x | x | |||||||
| Järvinen 2012 | x | x | x | x | x | ||||||
| Sengiku 2013 | x | x | x | ||||||||
| Inamoto 2013 | x | x | x | x | |||||||
| Rentsch 2014 | x | x | x | x | x | ||||||
| Hemdan 2014 | x | x | x | x | |||||||
| Martinez-Pineiro 2015 | x | x | x | x | x | ||||||
| Solsona 2015 | x | x | x | x | x | ||||||
| Arends 2016 | x | x | x | x | |||||||
| Nakai 2016 | x | x | x | x | x | ||||||
| PAPILLARY | Kaasinen 2000 | x | x | NA | x | ||||||
| Bilen 2000 | x | x | NA | x | x | ||||||
| Van der Meijden 2001 | x | x | NA | x | x | ||||||
| Nomata 2002 | x | NA | x | ||||||||
| Okamura 2002 | x | x | NA | x | |||||||
| Rajala 2002 | x | NA | |||||||||
| Kuroda 2004 | x | NA | x | x | x | ||||||
| Koga 2004 | x | NA | x | ||||||||
| Mitsumori 2004 | x | NA | x | ||||||||
| Cheng 2005 | x | x | NA | x | x | x | |||||
| Vijjan 2006 | x | x | NA | x | x | x | |||||
| Hinotsu 2006 | x | x | NA | x | |||||||
| Barghi 2006 | x | x | NA | x | |||||||
| Ojea 2007 | x | x | NA | x | x | ||||||
| El-Ghobashy 2007 | x | x | NA | x | |||||||
| Agrawal 2007 | x | NA | x | ||||||||
| Friedrich 2007 | x | NA | x | ||||||||
| Hendricksen 2008 | x | x | NA | x | |||||||
| Berrum-Svennung 2008 | x | x | NA | x | |||||||
| Isbarn 2008 | x | NA | x | ||||||||
| Böhle 2009 | x | x | NA | x | x | ||||||
| Gudjonsson 2009 | x | NA | |||||||||
| Järvinen 2009 | x | x | NA | x | x | x | |||||
| Seretta 2010 | x | x | NA | x | |||||||
| Sylvester 2010 | x | x | NA | x | x | x | x | ||||
| De Nunzio 2011 | x | x | NA | x | x | ||||||
| Di Stasi 2011 | x | x | NA | x | x | x | |||||
| Hinotsu 2011 | x | x | NA | x | x | ||||||
| Oddens 2013 | x | x | NA | x | x | x | x | ||||
| Huang 2015 | x | NA | x | x | x | ||||||
| Onishi 2017 | x | x | NA | x | |||||||
| Bijalwan 2017 | x | x | NA | x | |||||||
| TOTAL (n/%) | 56/57 (98%) | 42/57 (74%) | 10/25(40%) | 19/57 (33%) | 19/57 (33%) | 44/57 (77%) | 10/57(17%) | 21/57(37%) | 2/57 (3 %) | 1/57 (2 %) | |
| Number of individual verbatim outcomes | 35 | 20 | 14 | 10 | 11 | 36 | 14 | 6 | 2 | 2 | |